Microbiology and Immunology

You are here

Home > Publications > Publications

Publications

Found 437 results
Author Title Type [ Year(Asc)]
Filters: First Letter Of Last Name is C  [Clear All Filters]
2021
Liu W, Russell RM, Bibollet-Ruche F, Skelly AN, Sherrill-Mix S, Freeman DA, Stoltz R, Lindemuth E, Lee F-H, Sterrett S et al..  2021.  Predictors of Nonseroconversion after SARS-CoV-2 Infection.. Emerg Infect Dis. 27(9):2454-2458.
Yu EYoung, Zahid SS, Aloe S, Falck-Pedersen E, Zhou XKathy, Cheung N-KV, Lue NF.  2021.  Reciprocal impacts of telomerase activity and ADRN/MES differentiation state in neuroblastoma tumor biology.. Commun Biol. 4(1):1315.
Wang H, Xu M, Engelhart CA, Zhang X, Yan B, Pan M, Xu Y, Fan S, Liu R, Xu L et al..  2021.  Rediscovery of PF-3845 as a new chemical scaffold inhibiting phenylalanyl-tRNA synthetase in Mycobacterium tuberculosis.. J Biol Chem. 296:100257.
Chen X, Lee SKoo, Song M, Zhang T, Han MShin, Chen Y-T, Chen Z, Ma X, Tung C-H, Du Y-CNancy.  2021.  RHAMMB-mediated bifunctional nanotherapy targeting Bcl-xL and mitochondria for pancreatic neuroendocrine tumor treatment.. Mol Ther Oncolytics. 23:277-287.
Chen X, Lee SKoo, Song M, Zhang T, Han MShin, Chen Y-T, Chen Z, Ma X, Tung C-H, Du Y-CNancy.  2021.  RHAMMB-mediated bifunctional nanotherapy targeting Bcl-xL and mitochondria for pancreatic neuroendocrine tumor treatment.. Mol Ther Oncolytics. 23:277-287.
Chen X, Lee SKoo, Song M, Zhang T, Han MShin, Chen Y-T, Chen Z, Ma X, Tung C-H, Du Y-CNancy.  2021.  RHAMMB-mediated bifunctional nanotherapy targeting Bcl-xL and mitochondria for pancreatic neuroendocrine tumor treatment.. Mol Ther Oncolytics. 23:277-287.
Ray PC, Huggett M, Turner PA, Taylor M, Cleghorn LAT, Early J, Kumar A, Bonnett SA, Flint L, Joerss D et al..  2021.  Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth.. ACS Omega. 6(3):2284-2311.
Ray PC, Huggett M, Turner PA, Taylor M, Cleghorn LAT, Early J, Kumar A, Bonnett SA, Flint L, Joerss D et al..  2021.  Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth.. ACS Omega. 6(3):2284-2311.
Calderón F, Fairlamb AH, Strange M, Williams P, Nathan CF.  2021.  Surmounting structural barriers to tackle endemic infectious diseases.. J Exp Med. 218(9)
Barbet G, Nair-Gupta P, Schotsaert M, Yeung ST, Moretti J, Seyffer F, Metreveli G, Gardner T, Choi A, Tortorella D et al..  2021.  TAP dysfunction in dendritic cells enables noncanonical cross-presentation for T cell priming.. Nat Immunol. 22(4):497-509.
Yang HS, Racine-Brzostek SE, Karbaschi M, Yee J, Dillard A, Steel PAD, Lee WT, McDonough KA, Qiu Y, Ketas TJ et al..  2021.  Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients.. Biosens Bioelectron. 178:113008.
Yang HS, Racine-Brzostek SE, Karbaschi M, Yee J, Dillard A, Steel PAD, Lee WT, McDonough KA, Qiu Y, Ketas TJ et al..  2021.  Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients.. Biosens Bioelectron. 178:113008.
Yang HS, Racine-Brzostek SE, Karbaschi M, Yee J, Dillard A, Steel PAD, Lee WT, McDonough KA, Qiu Y, Ketas TJ et al..  2021.  Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients.. Biosens Bioelectron. 178:113008.
Aldridge BB, Barros-Aguirre D, Barry CE, Bates RH, Berthel SJ, Boshoff HI, Chibale K, Chu X-J, Cooper CB, Dartois V et al..  2021.  The Tuberculosis Drug Accelerator at year 10: what have we learned? Nat Med. 27(8):1333-1337.
Aldridge BB, Barros-Aguirre D, Barry CE, Bates RH, Berthel SJ, Boshoff HI, Chibale K, Chu X-J, Cooper CB, Dartois V et al..  2021.  The Tuberculosis Drug Accelerator at year 10: what have we learned? Nat Med. 27(8):1333-1337.
Aldridge BB, Barros-Aguirre D, Barry CE, Bates RH, Berthel SJ, Boshoff HI, Chibale K, Chu X-J, Cooper CB, Dartois V et al..  2021.  The Tuberculosis Drug Accelerator at year 10: what have we learned? Nat Med. 27(8):1333-1337.
2020
Wang H, Wang C, Peng G, Yu D, Cui X-G, Sun Y-H, Ma X.  2020.  Capping Protein Regulator and Myosin 1 Linker 3 Is Required for Tumor Metastasis.. Mol Cancer Res. 18(2):240-252.
Moallemian R, Rehman AUr, Zhao N, Wang H, Chen H, Lin G, Ma X, Yu J.  2020.  Immunoproteasome inhibitor DPLG3 attenuates experimental colitis by restraining NF-κB activation.. Biochem Pharmacol. 177:113964.
Song M, Wang C, Wang H, Zhang T, Li J, Benezra R, Chouchane L, Sun Y-H, Cui X-G, Ma X.  2020.  Targeting ubiquitin protein ligase E3 component N-recognin 5 in cancer cells induces a CD8+ T cell mediated immune response.. Oncoimmunology. 9(1):1746148.
Song M, Wang C, Wang H, Zhang T, Li J, Benezra R, Chouchane L, Sun Y-H, Cui X-G, Ma X.  2020.  Targeting ubiquitin protein ligase E3 component N-recognin 5 in cancer cells induces a CD8+ T cell mediated immune response.. Oncoimmunology. 9(1):1746148.
Gengenbacher M, Zimmerman MD, Sarathy JP, Kaya F, Wang H, Mina M, Carter C, Hossen MAmir, Su H, Trujillo C et al..  2020.  Tissue Distribution of Doxycycline in Animal Models of Tuberculosis.. Antimicrob Agents Chemother. 64(5)
2019
Quezada LLopez, Silve S, Kelinske M, Liba A, Gonzalez CDiaz, Kotev M, Goullieux L, Sans S, Roubert C, Lagrange S et al..  2019.  Bactericidal Disruption of Magnesium Metallostasis in Mycobacterium tuberculosis Is Counteracted by Mutations in the Metal Ion Transporter CorA.. mBio. 10(4)
Ringe RP, Pugach P, Cottrell CA, LaBranche CC, Seabright GE, Ketas TJ, Ozorowski G, Kumar S, Schorcht A, van Gils MJ et al..  2019.  Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes.. J Virol. 93(4)
Ringe RP, Pugach P, Cottrell CA, LaBranche CC, Seabright GE, Ketas TJ, Ozorowski G, Kumar S, Schorcht A, van Gils MJ et al..  2019.  Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes.. J Virol. 93(4)
Hu W, Zi Z, Jin Y, Li G, Shao K, Cai Q, Ma X, Wei F.  2019.  CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions.. Cancer Immunol Immunother. 68(3):365-377.